GBIC - Gulf Biomedical Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GBIC - Gulf Biomedical Corporation

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

From: jmhollen	6/3/2005 10:53:46 AM
	of 4

Gulf Biomedical Unveils New Formula for Erectile Dysfunction; New Formula to be Marketed Under LoveMagic Label This Month 05.31.05, 6:03 AM ET Gulf Biomedical Corporation (OTC: GBIC) today unveiled "LoveMagic(TM)", the second in the promised "Magic" series of new, safe, customer-friendly nutriceutical products to be marketed internationally on the internet. LoveMagic is an all-natural, herbal remedy which Gulf Biomedical expects to be an effective treatment for erectile dysfunction, and a "healthier" substitute for the Viagra and Cialis type of drug with out the side effects. LoveMagic's herbal pills are priced significantly below the cost of these brand drugs and will initially be sold through the internet in June of this year. Don West, President of GBIC stated, LoveMagic's unique formula of ingredients have demonstrated a beneficial effect in helping males achieve erection. With all the apprehension generated about the dangers of so many pharmaceutical products marketed by the massive industry, we feel it is time for a natural, risk-free product that can achieve the desired results at a fraction of the cost of other pharmaceutical products". Mr. West continued to state "We project a huge a market for LoveMagic. Our sales target for the year is anticipated to be announced within 30 to 45 days and will include our marketing plans for 2005." For more information please contact Investor Relations at (973) 351-3868. .

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext